Mutational specificity of aflatoxin B1. Comparison of in vivo host-mediated assay with in vitro S9 metabolic activation.
An intrasanguineous host-mediated assay was used to determine the pattern of mutagenesis induced by the carcinogen aflatoxin B1 in the lacI gene of Escherichia coli recovered from rat liver. To investigate the influence of different types of metabolic activation, the mutation spectrum induced by AFB1 activated in vitro by a commercially prepared S9 microsomal fraction from Aroclor 1254-treated rats was also obtained. A total of 281 forward mutations affecting the N-terminal region of the lacI gene were characterized by DNA sequencing analysis. AFB1 induced similar type of mutations with similar site specificity when activated by the standard S9 fraction or by employing a rat host-mediated assay. These results indicate the ability of the in vitro S9 fraction to mimic the in vivo metabolism, suggesting that the same active metabolite, presumably AFB1 8,9-epoxide, is responsible for generating a similar pattern of DNA damage, as reflected in the similarity of mutational spectra. For both activation systems, most mutations (>90%) were base substitutions that occurred primarily at G:C pairs. Somewhat over one-half of G:C targeted substitutions were GC>TA transversions, other mutations being evenly divided between G:C>AT transitions and GC>CG transversions. The mutational specificity exhibited by activated AFB1 can be explained by incorporation of different bases opposite a single type of non-instructive lesion during error-prone DNA synthesis. To what extent the mutations are due to the main adduct (AFB1-N7-Gua), its imidazole-ring-opened derivative or an apurinic site remains unknown.
Prieto-Alamo
M J
MJ
Departamento de Bioquímica y Biología Molecular, Universidad de Cordoba, Spain.
Jurado
J
J
Abril
N
N
Díaz-Pohl
C
C
Bolcsfoldi
G
G
Pueyo
C
C
D016604:Aflatoxin B1 / Q000378:metabolism* / Q000494:pharmacology*; D000818:Animals; D001426:Bacterial Proteins / Q000235:genetics; D001482:Base Composition; D001483:Base Sequence; D001711:Biotransformation; D004926:Escherichia coli / Q000187:drug effects / Q000235:genetics*; D029968:Escherichia coli Proteins; D016368:Frameshift Mutation; D005798:Genes, Bacterial / Q000187:drug effects*; D056968:Lac Repressors; D008862:Microsomes, Liver / Q000378:metabolism*; D009153:Mutagens / Q000378:metabolism / Q000494:pharmacology*; D017354:Point Mutation; D051381:Rats; D012097:Repressor Proteins / Q000235:genetics
D001426:Bacterial Proteins; D029968:Escherichia coli Proteins; D056968:Lac Repressors; C539064:LacI protein, E coli; D009153:Mutagens; D012097:Repressor Proteins; D016604:Aflatoxin B1